ION 269
Alternative Names: ION-269Latest Information Update: 21 Jan 2025
Price :
$50 *
At a glance
- Originator Ionis Pharmaceuticals
- Class Antidementias; Antisense oligonucleotides
- Mechanism of Action Amyloid beta-protein precursor inhibitors; Gene silencing
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease
Most Recent Events
- 15 Nov 2024 Phase-I clinical trials in Alzheimer's disease (In adults) in USA (Intrathecal) (NCT06673069)
- 08 Nov 2024 Preclinical trials in Alzheimer's disease in USA (Intrathecal) prior to November 2024 (NCT06673069)
- 06 Nov 2024 Ionis Pharmaceuticals plans to initiate a phase I/II HERO trial for Alzheimer Disease and Down Syndrome (intrathecal) (NCT06673069)